New diabetes-like drugs for heart failure with obesity
Part of Heart & circulation, Hormones & metabolism, Lungs & breathing clinical trials.
This study is testing whether a new class of medications, known as GLP-1/GIP receptor agonists, can help improve symptoms and heart health in people who have heart failure with preserved ejection fraction and are overweight or obese. It is a registry that tracks participants' health over time to learn about the treatment's effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older
- Your body mass index (BMI) is 30 or higher
- You have symptoms like shortness of breath when active, tiredness, or reduced exercise tolerance
- You have heart failure with preserved ejection fraction (your heart's pumping function is normal but the heart is stiff)
- You are able to have an exercise test while lying on your back
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether incretin-based diabetes medications (like GLP-1 drugs) can help people with a specific type of heart failure called HFpEF that is linked to obesity. The goal is to see if these drugs improve heart function and symptoms.
This study tests whether a new medication called NNC0487-0111 can help people with heart failure who also have obesity. Researchers will compare it to a placebo (inactive pill) to see if it improves heart function and overall health.
This study tests whether weight loss from a medication can improve how you feel, move, and how well your heart works. It's for people who have both obesity and heart failure with reduced pumping strength.
This trial tests whether pioglitazone (a diabetes medicine) helps people who have type 2 diabetes and a specific type of heart failure where the heart pumps normally. It may improve heart failure symptoms and function in carefully selected patients.
This study tests a new medicine called IBI362 for people with heart failure and obesity. The medicine may help improve symptoms and quality of life. You must have a specific type of heart failure (HFpEF or HFmrEF) and a BMI of 28 or higher.
This trial tests if dapagliflozin helps reduce fat around the heart in people with a type of heart failure where the heart pumps normally but is stiff. It might improve symptoms and overall health.
Hear when a new Heart Failure With Preserved Ejection Fraction trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.